TCGA-FD-A3B5-01A-11R-A20F-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 8.935611038
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.350
- PI3K_AKT_MTOR_SIGNALING+0.350
- HYPOXIA+0.340
- PROTEIN_SECRETION+0.320
- CHOLESTEROL_HOMEOSTASIS+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- GLYCOLYSIS+0.280
- MTORC1_SIGNALING+0.260
- G2M_CHECKPOINT+0.250
- HEDGEHOG_SIGNALING+0.240
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.400
- PANCREAS_BETA_CELLS-0.240
- INTERFERON_GAMMA_RESPONSE-0.160
- IL2_STAT5_SIGNALING-0.140
- KRAS_SIGNALING_UP-0.130
- DNA_REPAIR-0.120
- OXIDATIVE_PHOSPHORYLATION-0.110
- XENOBIOTIC_METABOLISM-0.110
- MYC_TARGETS_V2-0.090
- BILE_ACID_METABOLISM-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-O2-A52V-01A-31R-A262-07 | — | cohortSQ1 | 0.769 |
| 2 | SRR17866829 | — | — | 0.733 |
| 3 | TCGA-B6-A0RI-01A-11R-A056-07 | — | B | 0.728 |
| 4 | TCGA-85-7844-01A-11R-2125-07 | — | cohortSQ2 | 0.722 |
| 5 | MDT-AP-0007 | Med | Medulloblastoma | 0.719 |
| 6 | SRR8613786 | — | C | 0.714 |
| 7 | TCGA-E9-A1N6-01A-11R-A144-07 | — | C | 0.713 |
| 8 | TCGA-77-8145-01A-11R-2247-07 | — | cohortSQ1 | 0.711 |
| 9 | TCGA-BL-A13J-01A-11R-A10U-07 | — | — | 0.711 |
| 10 | MNG471 | — | — | 0.709 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.350 | Inavolisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.120 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |